Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Weight loss and dehydration requiring IV therapy or feeding support
Future iterations may achieve even higher bioavailability through improved SNAC technology or alternative permeation enhancers
These medications have delivered results that were, until recently, unimaginable outside of surgery: participants in clinical trials routinely lose 1520% of their body weight
Compounded vs FDA-Approved Formulations: Budget Implications Tesamorelin is FDA-approved as Egrifta (and Egrifta SV) for HIV-associated lipodystrophy, with branded pricing ranging from $4,500$6,000 per month before insurance
US$ 23.42
US$ 26.99
US$ 26.35
US$ 23.87
